Filtered By:
Drug: Rosuvastatin

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 159 results found since Jan 2013.

Adverse Effects of Statins
In Reply Dr Goldstein questions the relationship between cholesterol levels, statins, and hemorrhagic stroke. Evidence for the association between low –total serum cholesterol levels, which is mostly LDL-C, and an increased risk of hemorrhagic stroke has been available since at least the late 1980s. A meta-analysis of 23 studies including 1.4 million participants and 7960 hemorrhagic strokes found that the RR of hemorrhagic stroke was 38% higher (95% CI, 8%-59%) in patients with the highest vs lowest LDL-C values. The Cholesterol Treatment Trialists’ Collaboration meta-analysis of 26 trials showed a nonsignificant incr...
Source: JAMA - March 14, 2017 Category: Journals (General) Source Type: research

Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease.
CONCLUSIONS: The impact of individual oxidative stress markers differs with time after ischemic stroke, suggesting that different oxidative markers reflect different aspects of oxidative stress. In addition, short-term use of a statin exerts antioxidant effects against lipid peroxidation via lipid-lowering-dependent and -independent mechanisms, but not against protein or DNA oxidation in atherosclerotic stroke patients. PMID: 24829600 [PubMed]
Source: Journal of Clinical Neurology - December 2, 2014 Category: Neurology Tags: J Clin Neurol Source Type: research

A meta-analysis of pharmacological neuroprotection in noncardiac surgery: focus on statins, lidocaine, ketamine, and magnesium sulfate.
CONCLUSIONS: The available clinical data are still scarce. Our analyses indicate no protective effects by statins against perioperative stroke but some favorable trends toward delayed stroke. Further randomized trials are needed to unequivocally assess the neuroprotective potential of current pharmacological agents in non-cardiac surgery. PMID: 29630129 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - April 10, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Error in USPSTF Report on Statin Use
The 2016 review for the US Preventive Services Task Force on statins for prevention of cardiovascular disease in adults had errors in the analysis of statins vs placebo and cardiovascular mortality. For the JUPITER trial, we interpreted “MI, stroke or cardiovascular death” as reported in the main trial publication as “myocardial death, stroke death, or cardiovascular death,” when it meant “nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death.” Therefore, the analysis erroneously included nonfatal myo cardial infarction and stroke events (83/8901 vs 157/8901 in the rosuvastatin vs placebo gro...
Source: JAMA - February 18, 2020 Category: General Medicine Source Type: research

Rosuvastatin may stabilize atherosclerotic aortic plaque: Transesophageal echocardiographic study in the EPISTEME trial
This study sought to analyze the temporal profile of AAPs after rosuvastatin therapy in Japanese patients with acute ischemic stroke.
Source: Atherosclerosis - February 16, 2015 Category: Cardiology Authors: Yuji Ueno, Kazuo Yamashiro, Yasutaka Tanaka, Masao Watanabe, Nobukazu Miyamoto, Yoshiaki Shimada, Takuma Kuroki, Ryota Tanaka, Katsumi Miyauchi, Hiroyuki Daida, Nobutaka Hattori, Takao Urabe Source Type: research

High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis
Conclusions High-intensity statin therapy could effectively reduce the risk of stroke in patients with CKD. However, its effects on all-cause mortality, myocardial infarction, heart failure and renal protection remain unclear. Moreover, it is hard to draw conclusions on the safety assessment of intensive statin treatment in this particular population. More studies are needed to credibly evaluate the effects of high-intensity statin therapy in patients with CKD.
Source: BMJ Open - May 15, 2015 Category: Journals (General) Authors: Yan, Y.-L., Qiu, B., Wang, J., Deng, S.-B., Wu, L., Jing, X.-D., Du, J.-L., Liu, Y.-J., She, Q. Tags: Open access, Cardiovascular medicine, Pharmacology and therapeutics Research Source Type: research

Mortality and Associated Morbidities Following Traumatic Brain Injury in Older Medicare Statin Users
Conclusion: These findings provide valuable information for clinicians treating older adults with TBI as clinicians can consider, when appropriate, atorvastatin and simvastatin to older adults with TBI in order to decrease mortality and associated morbidities.
Source: The Journal of Head Trauma Rehabilitation - November 1, 2018 Category: Neurology Tags: Focus on Clinical Research and Practice Source Type: research

Statins for primary prevention of venous thromboembolism.
CONCLUSIONS: Available evidence showed that rosuvastatin was associated with a reduced incidence of VTE, but the evidence was limited to a single RCT and any firm conclusions and suggestions could be not drawn. Randomised controlled trials of statins (including rosuvastatin) are needed to evaluate their efficacy in the prevention of VTE. PMID: 25518837 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - December 18, 2014 Category: Journals (General) Authors: Li L, Zhang P, Tian JH, Yang K Tags: Cochrane Database Syst Rev Source Type: research

The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA)
Conclusion: Genetic variants strongly associated with CAD risk are not associated with the severity and outcome of ischemic heart failure. The observed association of the 1p13.3 locus with all-cause mortality requires confirmation in further studies.
Source: BMC Medical Genetics - December 21, 2014 Category: Genetics & Stem Cells Authors: Vincent HaverNiek VerweijJohn KjekshusJayne FoxHans WedelJohn WikstrandWiek van GilstRudolf de BoerDirk van VeldhuisenPim van der Harst Source Type: research

Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design and Participants’ Baseline Characteristics
Conclusions The HOPE-3 trial will provide new information on cholesterol and BP lowering in intermediate risk populations with average cholesterol and BP levels and is expected to inform approaches to primary prevention worldwide (HOPE-3 ClinicalTrials.gov number, NCT00468923). Teaser The HOPE-3 trial is a large international randomized trial evaluating whether cholesterol lowering with a statin, BP lowering with low doses of two antihypertensives and their combination safely reduce major CV events in people at intermediate risk, with no previous vascular events and with average cholesterol and BP levels. The trial enrolle...
Source: Canadian Journal of Cardiology - July 9, 2015 Category: Cardiology Source Type: research

The Jekyll and Hyde of Statins
By Drs. David Niesel and Norbert Herzog, Medical Discovery News Cholesterol-lowering drugs called statins are the most prescribed drug ever. About 30 percent of Americans are currently taking statins such as Crestor, Lipitor, Mevacor and Zocor. Overall, statins can be good thing, but as with all drugs, there are some negative effects. Statins lower cholesterol by inhibiting a protein called HMG-CoA reductase. Since high cholesterol levels are linked to heart disease, statins can reduce the risks of heart attack and stroke, two of the leading causes of death in the United States. Recent reports from the American Heart Assoc...
Source: Science - The Huffington Post - February 3, 2016 Category: Science Source Type: news

Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
Conclusions The HOPE-3 trial will provide new information on cholesterol and BP lowering in intermediate-risk populations with average cholesterol and BP levels and is expected to inform approaches to primary prevention worldwide (HOPE-3 ClinicalTrials.gov NCT00468923).
Source: Canadian Journal of Cardiology - February 25, 2016 Category: Cardiology Source Type: research

Benefit-risk assessment of HMG-CoA reductase inhibitors (statins): a discrete choice experiment
Conclusions The results of benefit–risk assessment from every perspective were somewhat consistent. This study demonstrated the feasibility of applying a discrete choice experiment in the benefit–risk assessment of drugs and encouraged the engagement of multiple stakeholders in the decision-making process.
Source: BMJ Open - February 25, 2016 Category: Journals (General) Authors: Wanishayakorn, T., Sornlertlumvanich, K., Ngorsuraches, S. Tags: Open access, Cardiovascular medicine, Health policy Research Source Type: research

The Oversimplification of Cholesterol Testing Can Be Deadly
Early every year, countless Americans embark on a new fitness regime. They go for a physical and maybe for a blood test to measure cholesterol levels. After a clean bill of health, they might train to run a 10K, a marathon or even an Iron man. But what if those tests do not provide a complete picture of your health? What if you are on the verge of a heart attack and have no idea? Before 30, when the human body is at its peak, it can take the strain of being pushed to the limit. As we age, however, cellular changes and the expression of genetic predispositions can dramatically alter our health. Conventional medical tests a...
Source: Healthy Living - The Huffington Post - April 6, 2016 Category: Consumer Health News Source Type: news

Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome 
.
We present a unique case of synchronous rhabdomyolysis and Ogilvie's syndrome in an 80-year-old lung cancer survivor following a recent ischemic stroke for which she was prescribed clopidogrel and rosuvastatin for secondary prevention, and maprotiline for post-stroke, new-onset insomnia and anxiety. The ADRs resolved on removal of the offending agents and initiation of conservative treatment. Retrospective pharmacogenetic testing of the patient's drug-metabolizing enzymes and transporters was performed to guide further management and prevent future potential drug interactions and ADRs. What is novel and conclusions: This i...
Source: International Journal of Clinical Pharmacology and Therapeutics - March 5, 2017 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research